Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

The Defense Health Agency Aurora, on behalf of the TRICARE Management Activity, has issued solicitation HT9402-26-Q-9104 to establish an integrated pharmacy benefits program for the Military Health System. Pursuant to 10 U.S.C. § 1074g and 32 CFR Section 199.21, the Department of Defense Pharmacy and Therapeutics Committee reviews the clinical and cost effectiveness of pharmaceutical agents to determine their placement on the Uniform Formulary. This review categorizes agents as generic, formulary, Basic Core Formulary, Extended Core Formulary, or non-formulary. For the February 2026 meeting, the committee will specifically evaluate several newly approved drugs, including Aqvesme, Forzinity, Omlonti, and Voyxact, across therapeutic classes such as metabolic, glaucoma, and nephrology agents.

This procurement is classified under NAICS code 325412, Pharmaceutical Preparation Manufacturing, and PSC code 6505, Drugs and Biologicals. The government intends to award Uniform Formulary Blanket Purchase Agreements and Uniform Formulary Additional Discount Program Agreements based on the committee’s decisions. The solicitation includes eight attachments providing pricing appendices, frequent questions, and specific drug list spreadsheets. A pre-quotation teleconference is scheduled for January 14, 2026, and the final response deadline for this notice is January 26, 2026.

The scope of this requirement covers the purchase of pharmaceutical agents for the Military Health System, with Stephanie Erpelding serving as the point of contact. Administrative instructions for submitting clinical questions and price quotations are detailed within the Request for Quotation documents. All responses must be submitted via email to the designated point of contact by the established deadlines to be considered for the resulting agreements.